UNION KOREA PHARM Debt-to-Equity Swap Under Rehabilitation Plan, Existing Shareholders Face Over 650% Dilution
UNION KOREA PHARM has decided on a third-party allotment capital increase through a debt-to-equity swap for rehabilitation claims and secured claims under the approved rehabilitation plan.
The new shares issued amount to 51,660,308 shares, a massive dilution of approximately 652% compared to the existing 7,912,828 shares outstanding.
The issue price is par value of 500 KRW, an approximately 82% discount to the current stock price of 2,725 KRW, severely impacting existing shareholders' value.
The purpose of the fund raising is debt repayment via equity conversion, focusing on financial restructuring without actual cash inflow.
The largest shareholder will change, and main allottees include Park Kwang-seok, Kookmin Bank, Korea Asset Management Corporation, Mark420, and Yeom Ho.
[AI Summary]UNION KOREA PHARM's capital increase via massive debt-to-equity swap under rehabilitation dilutes existing share value by over 650%. As the funds are solely for debt repayment, no growth catalyst is expected, negatively impacting the stock price. Investors should watch for equity value decline and management uncertainty from the change in controlling shareholder.
KOSDAQ Filing Information
[Correction of Description] Report on Major Events (Decision on Paid-in Capital Increase)